The genetic architecture of human brainstem structures and their involvement in common brain disorders
- PMID: 32782260
- PMCID: PMC7421944
- DOI: 10.1038/s41467-020-17376-1
The genetic architecture of human brainstem structures and their involvement in common brain disorders
Abstract
Brainstem regions support vital bodily functions, yet their genetic architectures and involvement in common brain disorders remain understudied. Here, using imaging-genetics data from a discovery sample of 27,034 individuals, we identify 45 brainstem-associated genetic loci, including the first linked to midbrain, pons, and medulla oblongata volumes, and map them to 305 genes. In a replication sample of 7432 participants most of the loci show the same effect direction and are significant at a nominal threshold. We detect genetic overlap between brainstem volumes and eight psychiatric and neurological disorders. In additional clinical data from 5062 individuals with common brain disorders and 11,257 healthy controls, we observe differential volume alterations in schizophrenia, bipolar disorder, multiple sclerosis, mild cognitive impairment, dementia, and Parkinson's disease, supporting the relevance of brainstem regions and their genetic architectures in common brain disorders.
Conflict of interest statement
Some authors received speaker’s honoraria from Lundbeck (T.E., G.B., and O.A.A.), Janssen Cilag (T.E.), Merck (E.H.), Sanofi Genzyme (E.H.), and Synovion (O.A.A). A.B. received speaker’s honoraria from Lundbeck, Otsuka, and Janssen Cilag and consultation fees from Biogen and Roche. J.B. has been a consultant to, member of advisory board of, and/or speaker for Shire, Roche, Medice, and Servier. E.G.C. has received personal fees from Almirall, Biogen, Merck, Roche and Teva, and grants and personal fees from Novartis and Sanofi. S.C. has received grant support from AstraZeneca as a coinvestigator and has served as a speaker for Otsuka. H.F.H. has received travel support, honoraria for advice or lecturing from Biogen Idec, Sanofi Genzyme, Merck, Novartis, Roche, and Teva and an unrestricted research grant from Novartis. N.I.L. has received consultation fees and travel support from Lundbeck. H.S. has received fees for advisory boards from ACImmune, Merck, and Novo Nordisk. P.S. has received honoraria for lecturing and travel support from Merck. M.T. has been member of advisory boards for Merck, IASIS Healthcare, ELPEN and FarmaSyn. M.Z. has received speaker fees for lectures, travel support and membership in advisory boards from Janssen Cilag, Lundbeck, Otsuka, Ferrer Pharma, Trommsdorff, Servier, and Roche. None of these external parties had any role in the analysis, writing or decision to publish this work. All other authors declare no competing interests.
Figures





References
-
- Guyenet PG. The sympathetic control of blood pressure. Nat. Rev. Neurosci. 2006;7:335–346. - PubMed
-
- Damasio A, Carvalho GB. The nature of feelings: evolutionary and neurobiological origins. Nat. Rev. Neurosci. 2013;14:143–152. - PubMed
-
- Fisman M. The brain stem in psychosis. Br. J. Psychiatry. 1975;126:414–422. - PubMed
-
- Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009;8:270–279. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical